600062 华润双鹤
已收盘 05-15 15:00:00
资讯
新帖
简况
每周股票复盘：华润双鹤（600062）钠钾镁钙注射液获批
证券之星 · 05-10
每周股票复盘：华润双鹤（600062）钠钾镁钙注射液获批
华润双鹤(600062.SH)子公司钠钾镁钙注射用浓溶液获得药品注册证书
智通财经 · 05-08
华润双鹤(600062.SH)子公司钠钾镁钙注射用浓溶液获得药品注册证书
每周股票复盘：华润双鹤（600062）尼麦角林片获批丰富产品线
证券之星 · 05-02
每周股票复盘：华润双鹤（600062）尼麦角林片获批丰富产品线
华润双鹤（600062）披露全资子公司尼麦角林片获得药品注册证书，4月29日股价上涨0.45%
证券之星 · 04-29
华润双鹤（600062）披露全资子公司尼麦角林片获得药品注册证书，4月29日股价上涨0.45%
股市必读：华润双鹤一季报 - 第一季度单季净利润同比下降4.30%
证券之星 · 04-27
股市必读：华润双鹤一季报 - 第一季度单季净利润同比下降4.30%
每周股票复盘：华润双鹤（600062）股东户数增至5.5万，一季报营收净利双降
证券之星 · 04-26
每周股票复盘：华润双鹤（600062）股东户数增至5.5万，一季报营收净利双降
华润双鹤(600062.SH)发布一季度业绩，归母净利润4.85亿元，同比下降4.30%
智通财经 · 04-24
华润双鹤(600062.SH)发布一季度业绩，归母净利润4.85亿元，同比下降4.30%
华润双鹤（600062）524.75万股限售股将于4月20日解禁，占总股本0.51%
中金财经 · 04-20
华润双鹤（600062）524.75万股限售股将于4月20日解禁，占总股本0.51%
华润医药(03320)附属华润双鹤发行不超10亿元公司债券
智通财经 · 03-26
华润医药(03320)附属华润双鹤发行不超10亿元公司债券
每周股票复盘：华润双鹤（600062）2025年净利增1.18%
证券之星 · 03-22
每周股票复盘：华润双鹤（600062）2025年净利增1.18%
华润双鹤：A股每股拟派发现金红利0.379元
证券日报 · 03-19
华润双鹤：A股每股拟派发现金红利0.379元
华润双鹤(600062.SH)发布2025年度业绩，归母净利润16.47亿元，同比增长1.18%
智通财经 · 03-19
华润双鹤(600062.SH)发布2025年度业绩，归母净利润16.47亿元，同比增长1.18%
华润双鹤(600062.SH)：丙戊酸钠口服溶液获得药品注册证书
智通财经 · 03-17
华润双鹤(600062.SH)：丙戊酸钠口服溶液获得药品注册证书
每周股票复盘：华润双鹤（600062）拟注销174,998股限制性股票
证券之星 · 03-15
每周股票复盘：华润双鹤（600062）拟注销174,998股限制性股票
华润双鹤（600062）披露召开2025年度业绩说明会公告，3月12日股价上涨0.33%
证券之星 · 03-12
华润双鹤（600062）披露召开2025年度业绩说明会公告，3月12日股价上涨0.33%
每周股票复盘：华润双鹤（600062）醋酸钠林格注射液获准上市
证券之星 · 03-08
每周股票复盘：华润双鹤（600062）醋酸钠林格注射液获准上市
华润双鹤最新公告：全资子公司醋酸钠林格注射液获得药品注册证书
证券之星 · 03-06
华润双鹤最新公告：全资子公司醋酸钠林格注射液获得药品注册证书
每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证
证券之星 · 03-01
每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证
华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%
证券之星 · 02-26
华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%
华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选
证券之星 · 02-10
华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选
公司概况
公司名称：
华润双鹤药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-22
主营业务：
华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务、输液业务、原料药业务。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、素钠、依诺肝素原料、辅酶Q10、S-Na盐。0号、压氏达、穗悦、贝奇灵、糖适平、卜可、冠爽、珂立苏、诺百益、小儿复方氨基酸注射液(19AA-I)、基础输液、BFS等产品获评中国化学制药行业各细分领域优秀产品品牌。
发行价格：
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":17.58,"timestamp":1778828400000,"preClose":17.72,"halted":0,"volume":5715744,"delay":0,"changeRate":-0.0079,"floatShares":1038000000,"shares":1039000000,"eps":1.5648,"marketStatus":"已收盘","change":-0.14,"latestTime":"05-15 15:00:00","open":17.7,"high":17.76,"low":17.51,"amount":101000000,"amplitude":0.0141,"askPrice":17.58,"askSize":156,"bidPrice":17.57,"bidSize":480,"shortable":0,"etf":0,"ttmEps":1.5648,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":17.72,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":19.49,"lowLimit":15.95,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038582511,"isCdr":false,"pbRate":1.51,"roa":"--","peRate":11.234663,"roe":"4.08%","epsLYR":1.5949,"committee":0.540832,"marketValue":18258000000,"turnoverRate":0.0055,"status":1,"floatMarketCap":18252000000},"requestUrl":"/m/hq/s/600062/wiki","defaultTab":"wiki","newsList":[{"id":"2634123114","title":"每周股票复盘：华润双鹤（600062）钠钾镁钙注射液获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2634123114","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634123114?lang=zh_cn&edition=full","pubTime":"2026-05-10 03:13","pubTimestamp":1778353990,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，华润双鹤报收于17.94元，较上周的17.85元上涨0.5%。本周，华润双鹤5月8日盘中最高价报18.08元。华润双鹤当前最新总市值186.32亿元，在化学制药板块市值排名25/150，在两市A股市值排名1186/5200。安徽双鹤于2023年6月启动研发，2024年11月提交上市申请并获受理，2026年4月29日获批，视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0010","BK0185","BK0175","BK0239","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633436007","title":"华润双鹤(600062.SH)子公司钠钾镁钙注射用浓溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2633436007","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633436007?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:13","pubTimestamp":1778231581,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司安徽双鹤药业有限责任公司(简称“安徽双鹤”)收到了国家药品监督管理局颁发的钠钾镁钙注射用浓溶液《药品注册证书》。钠钾镁钙注射用浓溶液用于通过中心静脉输注含浓葡萄糖或氨基酸的溶液时的电解质补充，以维持成人患者的电解质动态平衡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)子公司钠钾镁钙注射用浓溶液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0010","BK0028","BK0188","BK0175","600062","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647061","title":"每周股票复盘：华润双鹤（600062）尼麦角林片获批丰富产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632647061?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:26","pubTimestamp":1777667171,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，华润双鹤报收于17.85元，较上周的17.89元下跌0.22%。本周关注点来自公司公告汇总：尼麦角林片获药品注册证书，视同通过一致性评价。公司公告汇总华润双鹤全资子公司华润双鹤利民药业(济南)有限公司收到国家药监局颁发的尼麦角林片《药品注册证书》，规格为30mg，注册分类为化学药品3类，视同通过一致性评价。此次获批有助于丰富公司产品线，提升市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0185","BK0188","BK0010","BK0239","600062","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631152825","title":"华润双鹤（600062）披露全资子公司尼麦角林片获得药品注册证书，4月29日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631152825","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631152825?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:47","pubTimestamp":1777463273,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，华润双鹤报收于17.96元，较前一交易日上涨0.45%，最新总市值为186.53亿元。华润双鹤于2026年4月29日披露公告，其全资子公司华润双鹤利民药业（济南）有限公司近日收到国家药监局颁发的尼麦角林片《药品注册证书》，规格为30mg，注册分类为化学药品3类，视同通过一致性评价。双鹤利民于2022年启动研发，2024年11月提交上市申请并获受理，2026年4月21日获批。截至公告日，累计研发投入1,111.74万元。目前国内已有16家企业获批该药品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900060581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0028","BK0239","BK0175","BK0010","BK0188","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630334390","title":"股市必读：华润双鹤一季报 - 第一季度单季净利润同比下降4.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630334390","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630334390?lang=zh_cn&edition=full","pubTime":"2026-04-27 06:54","pubTimestamp":1777244052,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，华润双鹤报收于17.89元，下跌0.89%，换手率0.67%，成交量7.0万手，成交额1.26亿元。股本股东变化股东户数变动近日华润双鹤披露，截至2026年3月31日公司股东户数为5.5万户，较2月28日增加339.0户，增幅为0.62%。业绩披露要点财务报告华润双鹤2026年一季报显示，一季度公司主营收入28.07亿元，同比下降8.84%；归母净利润4.85亿元，同比下降4.3%；扣非净利润4.69亿元，同比下降3.51%；负债率27.79%，投资收益5830.67万元，财务费用1269.94万元，毛利率59.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700006880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630080296","title":"每周股票复盘：华润双鹤（600062）股东户数增至5.5万，一季报营收净利双降","url":"https://stock-news.laohu8.com/highlight/detail?id=2630080296","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630080296?lang=zh_cn&edition=full","pubTime":"2026-04-26 05:05","pubTimestamp":1777151115,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，华润双鹤报收于17.89元，较上周的18.3元下跌2.24%。本周，华润双鹤4月20日盘中最高价报18.29元。股本股东变化股东户数变动截至2026年3月31日，华润双鹤股东户数为5.5万户，较2月28日增加339.0户，增幅0.62%。业绩披露要点财务报告华润双鹤2026年一季报显示，一季度主营收入28.07亿元，同比下降8.84%；归母净利润4.85亿元，同比下降4.3%；扣非净利润4.69亿元，同比下降3.51%；负债率27.79%，投资收益5830.67万元，财务费用1269.94万元，毛利率59.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600002213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629816758","title":"华润双鹤(600062.SH)发布一季度业绩，归母净利润4.85亿元，同比下降4.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629816758","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629816758?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:33","pubTimestamp":1777019631,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)披露2026年第一季度报告，报告期公司实现营收28.07亿元，同比下降8.84%;归母净利润4.85亿元，同比下降4.30%;扣非净利润4.69亿元，同比下降3.51%。基本每股收益0.4694元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433354.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628794751","title":"华润双鹤（600062）524.75万股限售股将于4月20日解禁，占总股本0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628794751","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628794751?lang=zh_cn&edition=full","pubTime":"2026-04-20 08:10","pubTimestamp":1776643819,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，华润双鹤于4月20日将有524.75万股限售股份解禁，为公司股权激励限售股份，占公司总股本0.51%。最近一年内，该股累计解禁34.71万股，占总股本的0.03%。本次解禁后，公司还有35.71万股限售股份，占总股本0.03%。具体如下图所示：本次解禁涉及股东明细见下表：华润双鹤财务数据及主营业务：。 华润双鹤主营业务：慢病业务、专科业务和输液业务三大业务平台。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/20/20260420949924.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/20/20260420949924.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260420/32155805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0028","BK0175","BK0010","600062","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622519668","title":"华润医药(03320)附属华润双鹤发行不超10亿元公司债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2622519668","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622519668?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:03","pubTimestamp":1774523025,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润医药(03320)发布公告，公司非全资附属公司华润双鹤药业股份有限公司(华润双鹤)已于中国向合资格投资者发行首期公司债券(2026年公司债券)，本金总额不超过人民币10亿元，期限为3年，年息率为1.65%。发行首期2026年公司债券的所得款项净额将用于偿还计息债务及补充营运资金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","600062","BK1570","BK0028","03320","BK0239","BK0175","BK0010","BK0188","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621796250","title":"每周股票复盘：华润双鹤（600062）2025年净利增1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621796250","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621796250?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:14","pubTimestamp":1774116850,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，华润双鹤报收于18.65元，较上周的18.22元上涨2.36%。本周，华润双鹤3月20日盘中最高价报18.88元。本周关注点来自业绩披露要点：华润双鹤2025年归母净利润16.47亿元，同比上升1.18%。股本股东变化截至2026年2月28日，华润双鹤股东户数为5.46万户，较2025年12月31日减少1089户，减幅1.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","BK0175","BK0185","BK0188","BK0028","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620322990","title":"华润双鹤：A股每股拟派发现金红利0.379元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620322990","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620322990?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:41","pubTimestamp":1773927660,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月19日，华润双鹤发布公告称，公司董事会审议通过2025年度利润分配方案，拟向全体股东每10股派发现金红利3.79元（含税），即A股每股拟派发现金红利0.379元（含税）。本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将在权益分派实施公告中明确。该方案尚需提交股东会审议。（文章来源：证券日报）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-19/doc-inhrpspu1404738.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-19/doc-inhrpspu1404738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0188","BK0239","BK0175","600062","159982","BK0028","399300","BK0185","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620414412","title":"华润双鹤(600062.SH)发布2025年度业绩，归母净利润16.47亿元，同比增长1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620414412","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620414412?lang=zh_cn&edition=full","pubTime":"2026-03-19 18:52","pubTimestamp":1773917547,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤 发布2025年年度报告，报告期内，公司实现营业收入110.01亿元，同比下降1.88%。实现归属于上市公司股东的净利润16.47亿元，同比增长1.18%。拟向全体股东每10股派发现金红利3.79元(含税)。专科业务收入30.5亿元。抗病毒领域，治疗带状疱疹的抗病毒药溴夫定(吉时达)收入过亿，同比增长超350%。抗凝领域，依诺肝素钠注射液收入同比增长27%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620558440","title":"华润双鹤(600062.SH)：丙戊酸钠口服溶液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2620558440","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620558440?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:08","pubTimestamp":1773738530,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 华润双鹤(600062.SH)发布公告，近日，公司控股子公司湖南省湘中制药有限公司(以下简称“湘中制药”)收到了国家药品监督管理局(以下简称“国家药监局”)颁发的丙戊酸钠口服溶液《药品注册证书》。该药品获得《药品注册证书》，将进一步丰富公司产品线，有助于提升公司产品的市场竞争力，并为后续其他产品研发积累了宝贵的经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：丙戊酸钠口服溶液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","600062","BK0185","BK0028","BK0010","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619178829","title":"每周股票复盘：华润双鹤（600062）拟注销174,998股限制性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2619178829","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619178829?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:34","pubTimestamp":1773513252,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，华润双鹤报收于18.22元，较上周的18.2元上涨0.11%。本周，华润双鹤3月13日盘中最高价报18.35元。公司公告汇总：华润双鹤将于2026年3月20日召开2025年度业绩说明会。公司公告汇总北京市中伦律师事务所就华润双鹤药业股份有限公司2021年限制性股票激励计划部分限制性股票回购注销实施出具法律意见书。华润双鹤药业股份有限公司因3名激励对象不再符合激励条件，拟回购注销其已获授但尚未解除限售的限制性股票共计174,998股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","BK0188","BK0185","BK0010","600062","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618413018","title":"华润双鹤（600062）披露召开2025年度业绩说明会公告，3月12日股价上涨0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413018","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618413018?lang=zh_cn&edition=full","pubTime":"2026-03-12 22:38","pubTimestamp":1773326298,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，华润双鹤报收于18.23元，较前一交易日上涨0.33%，最新总市值为189.37亿元。该股当日开盘18.18元，最高18.24元，最低18.12元，成交额达8560.74万元，换手率为0.46%。华润双鹤近日发布《关于召开2025年度业绩说明会的公告》。公告显示，公司将于2026年3月20日15:00至17:10召开2025年度业绩说明会，介绍公司2025年度经营成果和财务状况。投资者可于2026年3月18日16:00前通过指定网址、二维码或公司邮箱mss@dcpc.com提交问题。说明会后公司将披露会议召开情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200039018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0010","BK0175","BK0188","BK0239","600062","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617366871","title":"每周股票复盘：华润双鹤（600062）醋酸钠林格注射液获准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2617366871","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617366871?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:27","pubTimestamp":1772908030,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，华润双鹤报收于18.2元，较上周的18.4元下跌1.09%。本周关注点公司公告汇总：全资子公司醋酸钠林格注射液获药品注册证书公司公告汇总：该药品注册分类为化学药品3类，视同通过一致性评价公司公告汇总：截至公告日，该项目累计研发投入146.64万元公司公告汇总华润双鹤全资子公司西安京西双鹤药业有限公司研发的醋酸钠林格注射液于2026年2月25日获得国家药监局批准上市，注册分类为化学药品3类，视同通过一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600062","BK0028","BK0188","BK0239","BK0175","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617168627","title":"华润双鹤最新公告：全资子公司醋酸钠林格注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2617168627","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617168627?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:30","pubTimestamp":1772789445,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，公司全资子公司西安京西双鹤药业有限公司收到国家药监局颁发的醋酸钠林格注射液《药品注册证书》。该药品用于循环血容量及组织间液减少时细胞外液的补充，代谢性酸中毒的纠正。京西双鹤于2023年11月启动该药品的仿制药研发工作，于2024年9月提交上市许可申请，并于2026年2月获得批准上市。根据国家相关政策规定，本次获得《药品注册证书》视同通过一致性评价。截至公告日，公司针对该药品累计研发投入为146.64万元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600028516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0239","BK0188","BK0185","BK0010","600062","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616784393","title":"每周股票复盘：华润双鹤（600062）平衡盐冲洗液获注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784393","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616784393?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:00","pubTimestamp":1772301642,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，华润双鹤报收于18.4元，较上周的18.31元上涨0.49%。本周，华润双鹤2月26日盘中最高价报18.58元。来自公司公告汇总：固体制剂、注射剂等多条生产线通过GMP符合性检查。来自公司公告汇总：平衡盐冲洗液国内市场规模达5,585万元，已有多家企业布局。华润双鹤全资子公司西安京西双鹤药业有限公司研发的平衡盐冲洗液获得国家药品监督管理局颁发的药品注册证书，规格为500ml、1000ml，注册分类为化学药品3类，视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","600062","BK0010","BK0188","BK0239","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614023937","title":"华润双鹤（600062）披露通过GMP符合性检查公告，2月26日股价下跌0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614023937","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614023937?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:49","pubTimestamp":1772117352,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，华润双鹤报收于18.46元，较前一交易日下跌0.16%，最新总市值为191.75亿元。该股当日开盘18.53元，最高18.58元，最低18.42元，成交额达9432.26万元，换手率为0.49%。近日，华润双鹤药业股份有限公司收到北京市药品监督管理局颁发的《药品GMP符合性检查告知书》，公司固体制剂车间硬胶囊剂生产线、注射剂车间小容量注射剂K线、冻干车间半固体制剂生产线通过GMP符合性检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","BK0185","BK0010","600062","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610291648","title":"华润双鹤最新公告：部分药品在国家组织集采药品协议期满品种接续采购中拟中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2610291648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610291648?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:27","pubTimestamp":1770715647,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，2026年2月9日，公司及部分下属子公司的缬沙坦氢氯噻嗪片、硝苯地平缓释片(Ⅱ)、硝苯地平控释片、厄贝沙坦分散片、依诺肝素钠注射液等药品拟中选集采药品协议期满品种接续采购，上述主要拟中选药品系公司参与本次接续采购的药品中收入规模排名前五的品种，除上述主要拟中选药品外，公司另有阿法骨化醇软胶囊等48个药品参与本次接续采购并拟中选。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000028171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","BK0175","BK0010","600062","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778844862468,"stockEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0322},{"period":"6month","weight":-0.0945},{"period":"1year","weight":-0.0408},{"period":"ytd","weight":-0.0312}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0376},{"period":"3month","weight":0.0235},{"period":"6month","weight":0.047},{"period":"1year","weight":0.2274},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54972人(较上一季度增加0.62%)","perCapita":"18886股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103858万元","survey":" 华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务、输液业务、原料药业务。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、素钠、依诺肝素原料、辅酶Q10、S-Na盐。0号、压氏达、穗悦、贝奇灵、糖适平、卜可、冠爽、珂立苏、诺百益、小儿复方氨基酸注射液(19AA-I)、基础输液、BFS等产品获评中国化学制药行业各细分领域优秀产品品牌。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}